Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Injection vs Ozempic in Chinese Patients with Type 2 Diabetes
ChiCTR2400088755Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change from baseline in HbA1c at week 32. Started Aug 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400088755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088755.